2021年3月1日
SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals
Scientific Reports
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 11
- 号
- 1
- 記述言語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1038/s41598-021-85202-9
The aim of this study is to understand adaptive immunity to SARS-CoV-2 through the analysis of B cell epitope and neutralizing activity in coronavirus disease 2019 (COVID-19) patients. We obtained serum from forty-three COVID-19 patients from patients in the intensive care unit of Osaka University Hospital (n = 12) and in Osaka City Juso Hospital (n = 31). Most individuals revealed neutralizing activity against SARS-CoV-2 assessed by a pseudotype virus-neutralizing assay.The antibody production against the spike glycoprotein (S protein) or receptor-binding domain (RBD) of SARS-CoV-2 was elevated, with large individual differences, as assessed by ELISA. We observed the correlation between neutralizing antibody titer and IgG, but not IgM, antibody titer of COVID-19 patients. In the analysis of the predicted the linear B cell epitopes, hot spots in the N-terminal domain of the S protein were observed in the serum from patients in the intensive care unit of Osaka University Hospital. Overall, the analysis of antibody production and B cell epitopes of the S protein from patient serum may provide a novel target for the vaccine development against SARS-CoV-2.
- リンク情報
-
- DOI
- https://doi.org/10.1038/s41598-021-85202-9
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/33723294
- Scopus
- https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85102581977&origin=inward 本文へのリンクあり
- Scopus Citedby
- https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85102581977&origin=inward
- ID情報
-
- DOI : 10.1038/s41598-021-85202-9
- eISSN : 2045-2322
- PubMed ID : 33723294
- SCOPUS ID : 85102581977